Below is the list of clinical trials currently available at the Cancer Institute of Florida Hospital Memorial Medical Center.
For any questions or to learn if you qualify for a trial, please contact our clinical trial research coordinator at (386) 231-4023.
Breast Cancer Studies
#311-06-EP Breast Cancer Collaborative Registry Trial (BCCR): A Breast Cancer Information Registry for Participants with Breast Cancer or Characteristics of Hereditary Breast Cancer.
Lung Cancer Studies
LUN 298/ GO29437: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin +Paclitaxel or MPDL3280A In Combination with Carboplatin + Nab-Paclitaxel Versus Carboplatin + Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NCT02367794)
LUN 299/GO29537: A Phase III, Multicenter, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Nab-Paclitaxel For Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NCT02367781)
LUN 308/ GO29527: A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Atezolizumab, Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Chemotherapy in Patients With Lung Cancer (NCT02486718)
https://clinicaltrials.gov/ct2/show/NCT02486718 (coming soon)
Amgen 20110266: A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Amgen 20120139: "A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec." (coming soon)
A221101 “A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodfinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma."